

AD \_\_\_\_\_

Award Number: DAMD17-99-1-9576

TITLE: Roundtable on Biomedical Engineering Materials and  
Applications

PRINCIPAL INVESTIGATOR: Richard Chait, Ph.D.  
Teri Thorowgood  
Dr. Toni Marechaux

CONTRACTING ORGANIZATION: National Academy of Sciences  
Washington, DC 20418

REPORT DATE: September 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20021115 051

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2002	3. REPORT TYPE AND DATES COVERED Final (1 Sep 99 - 31 Aug 02)	
4. TITLE AND SUBTITLE  Roundtable on Biomedical Engineering Materials and Applications			5. FUNDING NUMBERS DAMD17-99-1-9454	
6. AUTHOR(S) Richard Chait, Ph.D. Teri Thorowgood Dr. Toni Marechaux				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  National Academy of Sciences Washington, DC 20418  E-Mail: tthorowg@nas.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words)  The National Materials Advisory Board (NMAB) held a BEMA Roundtable workshop on 07-08 February 2002 (postponed from 04-05 October 2001 due to issues pertaining to 9/11 terrorist attack) at the National Research Council (NRC), Washington DC. The invited speakers were Dr. David Feigal, Director for the Center for Devices and Radiological Health, US Food and Drug Administration; Ron Greene, Wilmer, Cutler & Pickering; Barbara Rather, Dow Corning; Nelson Lazear, Bayer; James Harper, PolicyCounsel.com; and George Brode, Integra LifeSciences. The speakers addressed the topic of pathways to innovation, including examining the current status and gauge the effects of biomaterials shortages, identifying key barriers to biomaterial availability, and discussing forging biomaterials supplier. The meeting provided opportunities to explore with key stakeholders and decision makers future options in assuring biomaterials availability.  NMAB held the fourth BEMA meeting on 22-23 July 2002 at the NRC's J. Erik Jonsson Woods Hole Center, Woods Hole, MA. The technical speakers were Nancy Parenteau, Amaranth Bio, Inc.; Joshua Jacobs, Rush University Medical College; Eric Amis, NIST; Doyle Gantt, FDA, Center for Devices and Radiological Health; Anthony Ratcliffe, Advanced Tissue Sciences; Jack Lemons, University of Alabama - Birmingham; Rodney White, UCLA; John Watson, National Institutes of Health; and Michael Jaffe, Medical Device Concept Laboratory. The meeting goals were to continue planning for a "Science-Based Testing" workshop, now scheduled for 11-12 February of 2003, and to discuss issues of interest including implant retrieval (and associated logistics, database issues, privacy, etc); differentiation of biologics, devices, and combination products; industry perspective of where advanced biomedical materials are headed and their related testing requirements (e.g., nano, MEMS, tissue engineering), and current testing protocols.				
14. SUBJECT TERMS biomedical, materials, roundtable			15. NUMBER OF PAGES 5	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

<b>Cover.....</b>	<b>1</b>
<b>SF 298.....</b>	<b>2</b>
<b>Table of Contents.....</b>	<b>3</b>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>4</b>
<b>Reportable Outcomes.....</b>	<b>5</b>
<b>Conclusions.....</b>	<b>5</b>

## **Introduction**

The Biomedical Engineering Materials and Applications (BEMA) Roundtable will provide a forum for identifying major opportunities for applying engineering principles to create and improve clinical performance of medically useful materials and devices, including implants, as well as for discussion of strategies for overcoming obstacles—technical, legal, or cultural—that impede transition of new materials and devices to clinical application.

## **Body**

### **Roundtable Meetings**

The National Materials Advisory Board (NMAB) held a BEMA Roundtable workshop on 07-08 February 2002 (postponed from 04-05 October 2001 due to issues pertaining to 9/11 terrorist attack) at the National Research Council (NRC), Washington DC. The invited speakers were Dr. David Feigal, Director for the Center for Devices and Radiological Health, US Food and Drug Administration; Ron Greene, Wilmer, Cutler & Pickering; Barbara Rather, Dow Corning; Nelson Lazear, Bayer; James Harper, PolicyCounsel.com; and George Brode, Integra LifeSciences. The speakers addressed the topic of “pathways to innovation,” including examining the current status and gauge the effects of biomaterials shortages, identifying key barriers to biomaterial availability, and discussing forging biomaterials supplier. The workshop provided opportunities to explore with key stakeholders and decision makers future options in assuring biomaterials availability.

NMAB held the fourth BEMA on 22-23 July 2002 at NRC’s J. Erik Jonsson Woods Hole Center, Woods Hole, MA. The technical speakers were Nancy Parenteau, Amaranth Bio, Inc.; Joshua Jacobs, Rush University Medical College; Mark Kramer, FDA; Eric Amis, NIST; Doyle Gantt, FDA, Center for Devices and Radiological Health; Anthony Ratcliffe, Advanced Tissue Sciences; Jack Lemons, University of Alabama – Birmingham; Rodney White, UCLA; and Michael Jaffe, Medical Device Concept Laboratory. The meeting goals were to continue planning for a “Science-Based Testing” workshop and to discuss issues of interest including implant retrieval (and associated logistics, database issues, privacy, etc); differentiation of biologics, devices, and combination products; industry perspective of where advanced biomedical materials are headed and their related testing requirements (e.g., nano, MEMS, tissue engineering), and current testing protocols.

The fifth BEMA meeting is scheduled for 19-20 December 2002, to continue planning for the “Science-Based Testing” workshop, now scheduled for 11-12 February 2003.

### **Key Research Accomplishments**

- A BEMA workshop held, covering topics on “pathways to innovation” in biomaterial research and device innovation.
- Conference call meetings of "science-based testing" planning group
- A BEMA meeting covering topics of science-based testing
- Dates set for next BEMA meeting and for BEMA Workshop

## Reportable Outcomes

### Workshop Presentations by

- Dr. David Feigal, Director for the Center for Devices and Radiological Health, US Food and Drug Administration – **FDA Regulatory Perspectives**
- Ron Greene, Wilmer, Cutler & Pickering – **Biomaterials Access Assurance Act: Background and Intent of the Act**
- Barbara Rather, Dow Corning; Nelson Lazear, Bayer – **Biomaterials Access Assurance Act: Supplier Perspectives**
- James Harper, PolicyCounsel.com – **Biomaterials Access Assurance Act: Legislative Perspective**
- Julio Palmaz, UTHSCSA – **Interfacial Approach to Vascular Biomaterials**

### Meeting Presentations by:

- Alan Goldstein, Alfred University – **Science-based Testing: Discussion of Issues and Envisioning the science-based testing meeting**
- Mark Kramer, FDA – **Science-based testing: Regulation of Combination Products**
- Nancy Parenteau, Amaranth Bio, Inc. – **Science-based testing: Scientific Challenges for Combination Products**
- Joshua Jacobs, Rush University Medical College – **Current ASTM Testing Standards**
- Eric Amis, NIST – **Adopting Combinatorial and High-Throughput Approaches to Measurements at the Bio-Material Interface**
- Doyle Gantt, FDA, Center for Devices and Radiological Health – **Government Agency Perspective**
- Anthony Ratcliffe, Advanced Tissue Sciences – **Industry Perspective**
- Jack Lemons, University of Alabama – **Academic Perspective**
- Rodney White, UCLA – **Lifeline Registry Implant Retrieval Program**
- Michael Jaffe, Medical Device Concept Laboratory Materials – **Medicine, Devices, and Bioterrorism Overview**

## Conclusions

The BEMA Roundtable held a workshop and a meeting in the past year, providing forums to discuss biomaterials innovation and risk, device innovation, and science-based biomaterials testing. The BEMA will meet in December 2002 to discuss and continue planning for the upcoming 2003 "Science-Based Testing" workshop.